AptarGroup, Inc.

NYSE:ATR Aktierapport

Börsvärde: US$7.8b

AptarGroup Framtida tillväxt

Future kriterier kontrolleras 1/6

AptarGroup förväntas öka intäkter och intäkter med 7.8% respektive 5.7% per år. EPS förväntas tillväxt med 7.5% per år. Avkastningen på eget kapital förväntas bli 12.6% om 3 år.

Viktig information

7.8%

Tillväxttakt i vinsten

7.47%

Tillväxttakt för EPS

Packaging vinsttillväxt23.3%
Intäkternas tillväxttakt5.7%
Framtida avkastning på eget kapital12.60%
Bevakning av analytiker

Good

Senast uppdaterad04 May 2026

Senaste uppdateringarna om framtida tillväxt

Analysartikel • May 03

Analyst Estimates: Here's What Brokers Think Of AptarGroup, Inc. (NYSE:ATR) After Its First-Quarter Report

Shareholders might have noticed that AptarGroup, Inc. ( NYSE:ATR ) filed its first-quarter result this time last week...

Recent updates

Analysartikel • May 03

Analyst Estimates: Here's What Brokers Think Of AptarGroup, Inc. (NYSE:ATR) After Its First-Quarter Report

Shareholders might have noticed that AptarGroup, Inc. ( NYSE:ATR ) filed its first-quarter result this time last week...
Analysuppdatering • Apr 28

ATR: Nasal Therapies And Share Buybacks Will Support Future Upside

Analysts have kept their $144.00 price target on AptarGroup unchanged, citing relatively steady assumptions around discount rate, revenue growth, profit margin, and future P/E. These factors support the view that the stock’s current valuation framework still holds.
Analysuppdatering • Apr 14

ATR: Nasal Drug Delivery Pipeline And Leadership Transition Will Shape Future Upside

Analysts have reaffirmed AptarGroup's price target at $144.00, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E that together suggest a steady view of the company’s valuation. What's in the News AptarGroup’s Unidose Powder Nasal Spray System is being used in ENA Respiratory’s Phase II study of INNA-051, an investigational once-weekly nasal spray aimed at helping protect adults at higher risk from symptomatic viral respiratory infections (Key Developments).
Analysuppdatering • Mar 30

ATR: Nasal And Eye Care Drug Delivery Will Drive Future Upside

Analysts have raised their price target on AptarGroup from $133 to $144. This reflects updated views on its fair value based on revised assumptions for discount rate, revenue growth, profit margin, and future P/E.
Analysuppdatering • Mar 16

ATR: Share Repurchases Will Support Upside Potential In Drug Delivery Portfolio

Analysts have modestly revised their price target on AptarGroup, keeping fair value steady at about $212.79 while fine tuning assumptions on discount rate, revenue growth, profit margin and future P/E. This reflects updated views on the company’s risk profile and earnings potential.
Analysuppdatering • Mar 02

ATR: Share Repurchases And Nasal Drug Delivery Portfolio Will Support Upside Potential

Analysts have trimmed their price target on AptarGroup slightly to about $213, reflecting updated assumptions around a modestly higher discount rate, a small change in estimated fair value and adjusted expectations for revenue growth, profit margins and future P/E levels. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.
Analysuppdatering • Feb 16

ATR: Drug Delivery Platforms And Buybacks Will Support Attractive Future Returns

Analysts have raised their price target for AptarGroup to $161.43 from $159.14, reflecting updated views on the company’s discount rate, revenue growth assumptions, profit margin outlook, and future P/E expectations. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.
Analysuppdatering • Feb 02

ATR: Nasal And Eye Care Drug Delivery Platforms Will Support Balanced Outlook

AptarGroup's analyst price target has changed from US$153 to US$133 as analysts incorporate updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News AptarGroup's LuerVax and Spray Divider nasal delivery systems are being used in CastleVax's Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate that is being assessed against an FDA approved injectable mRNA vaccine in around 200 U.S. adults, including higher risk and older participants (Key Developments).
Analysuppdatering • Jan 19

ATR: Nasal And Eye Drug Delivery Platforms Will Support Attractive Future Returns

Analysts have trimmed their price target on AptarGroup to about $159 from roughly $161, reflecting slightly adjusted assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E that remain broadly consistent with prior views. What's in the News AptarGroup’s nasal vaccine delivery systems, LuerVax and Spray Divider, are being used in CastleVax’s Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate assessing safety, tolerability and immune response versus an FDA approved injectable mRNA vaccine in about 200 U.S. adults, including higher risk and older participants (Key Developments).
Analysuppdatering • Jan 05

ATR: Pharma Nasal Delivery Momentum Will Drive Attractive Long Term Returns

Narrative Update on AptarGroup Analyst Price Target Analysts have modestly raised their price target for AptarGroup to approximately 161.43 dollars, reflecting slightly higher long term return expectations and a marginally richer future earnings multiple. What's in the News Aptar's Bidose liquid nasal spray system has been selected to deliver the newly FDA approved CARDAMYST nasal spray for acute PSVT episodes in adults, which underscores Aptar's role in emergency cardiovascular therapies (FDA announcement) The company completed a 1.50 million share repurchase, about 2.27 percent of shares outstanding, for approximately 227.34 million dollars under its October 2024 buyback program, which signals continued capital return to shareholders (company disclosure) Nasus Pharma extended and updated its long running collaboration with Aptar through a new master services agreement that covers development, analytical, regulatory, and consulting support for its intranasal epinephrine program using Aptar's unit dose powder nasal delivery system (Nasus Pharma announcement) A new supply agreement makes Aptar France the exclusive provider of UDSp devices to Nasus Pharma for its intranasal epinephrine products, with milestone payments and royalties tied to NDA submission, approval, and commercial sales (Nasus Pharma announcement) Valuation Changes Fair value estimate: unchanged at approximately 161.43 dollars per share, indicating no revision to the intrinsic value assessment.
Analysartikel • Jan 02

We Like These Underlying Return On Capital Trends At AptarGroup (NYSE:ATR)

To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...
Analysuppdatering • Dec 15

ATR: Share Repurchases And Nasal Drug Delivery Partnership Will Support Upside Potential

Narrative Update Analysts have modestly reduced their price target on AptarGroup, trimming fair value expectations from approximately $220.00 to about $213.03. They cite updated assumptions for slower revenue growth, slightly lower profit margins, and a higher future price to earnings multiple within their discounted cash flow framework.
Analysuppdatering • Nov 30

ATR: Share Buyback and Expanded Pharma Partnerships Will Drive Future Upside

Analysts have slightly raised their price target for AptarGroup to $161.43, citing a modest increase in expected profit margins as well as an updated outlook on revenue growth and future price-to-earnings ratios. What's in the News Between July and September 2025, AptarGroup completed the repurchase of over 1.5 million shares for approximately $227.34 million as part of its ongoing buyback program (Company Filing).
Analysuppdatering • Nov 16

ATR: Share Buyback and Pharma Supply Moves Will Unlock Upside

Narrative Update on AptarGroup Price Target Analysts have revised AptarGroup’s fair value estimate downward by approximately $9 to $161.43 per share, citing tempered growth projections and a modest increase in the discount rate as key factors behind the adjustment. What's in the News Completed share repurchases totaling 1,504,552 shares for $227.34 million under the buyback announced on October 10, 2024 (Buyback Tranche Update).
Seeking Alpha • Nov 02

AptarGroup: Pharma Setback Creates Long-Term Opportunities

Summary AptarGroup's shares have dropped over 25% from summer highs due to slower growth, especially in high-margin pharma emergency solutions. ATR's valuation has compressed from 26x to 20x earnings, reflecting concerns about flat growth and a soft outlook for 2026. Pharma remains the most profitable segment, but headwinds in emergency-use delivery systems are expected to impact revenues next year. While the stock is approaching attractive valuation territory, risks remain for earnings growth in 2026, making the opportunity reasonable but not extremely compelling yet. Read the full article on Seeking Alpha
Analysuppdatering • Nov 01

ATR: Expanded Partnership Agreements Will Drive Long-Term Healthcare Solutions

Analysts have revised their price target for AptarGroup downward from $177 to $170.71. They cited modest changes in discount rate expectations, a slight increase in projected revenue growth, and softer projected profit margins and future valuation multiples.
Analysartikel • Oct 18

AptarGroup (NYSE:ATR) Is Increasing Its Dividend To $0.48

The board of AptarGroup, Inc. ( NYSE:ATR ) has announced that it will be increasing its dividend by 6.7% on the 13th of...
Analysuppdatering • Sep 05

Advanced Drug Delivery And Sustainable Packaging Will Transform Global Healthcare

The uptick in AptarGroup’s consensus price target to $178.43 is primarily driven by a modest increase in its forward P/E multiple, while revenue growth expectations remain stable. What's in the News Held Analyst/Investor Day.
Analysartikel • Aug 28

AptarGroup, Inc.'s (NYSE:ATR) Business Is Trailing The Market But Its Shares Aren't

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...
Analysartikel • Jul 15

AptarGroup's (NYSE:ATR) Dividend Will Be $0.45

AptarGroup, Inc. ( NYSE:ATR ) will pay a dividend of $0.45 on the 14th of August. The dividend yield is 1.1% based on...
Analysartikel • Jul 02

Are Investors Undervaluing AptarGroup, Inc. (NYSE:ATR) By 28%?

Key Insights AptarGroup's estimated fair value is US$220 based on 2 Stage Free Cash Flow to Equity Current share price...
Analysartikel • Jun 19

These 4 Measures Indicate That AptarGroup (NYSE:ATR) Is Using Debt Reasonably Well

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analysartikel • May 13

AptarGroup's (NYSE:ATR) Returns Have Hit A Wall

If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...
Seeking Alpha • Dec 02

AptarGroup Has Gotten Too Expensive

Summary AptarGroup specializes in niche packaging solutions for pharmaceuticals, beauty, food, and personal care, with impressive growth and a strong market presence. Despite recent stock performance, I find AptarGroup shares expensive, leading me to downgrade from 'hold' to a 'soft sell' rating. The company's financials show revenue and profitability growth, but valuation metrics indicate shares are overvalued compared to peers. AptarGroup's robust balance sheet and share buyback program are positives, but high trading multiples warrant a more cautious investment stance. Read the full article on Seeking Alpha
User avatar
Ny analys • Aug 25

Proprietary Drug Delivery And Digital Health Innovations To Spearhead Revenue Surge

Expansion in digital health services and sustainability initiatives may enhance brand value and open up new market opportunities, driving future growth.

Prognoser för vinst- och omsättningstillväxt

NYSE:ATR - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/20284,455437N/A7453
12/31/20274,1774024467448
12/31/20263,9833493836678
3/31/20263,873387324606N/A
12/31/20253,777393295570N/A
9/30/20253,663419306565N/A
6/30/20253,611392342616N/A
3/31/20253,555370356634N/A
12/31/20243,583375349643N/A
9/30/20243,573336378685N/A
6/30/20243,557320323629N/A
3/31/20243,543313254569N/A
12/31/20233,487284257575N/A
9/30/20233,445281209528N/A
6/30/20233,389251159484N/A
3/31/20233,337232164485N/A
12/31/20223,322239163479N/A
9/30/20223,34023888410N/A
6/30/20223,32923146365N/A
3/31/20223,29522366383N/A
12/31/20213,22724456363N/A
9/30/20213,163240156448N/A
6/30/20213,096256256518N/A
3/31/20212,985243307557N/A
12/31/20202,929214318570N/A
9/30/20202,851209283516N/A
6/30/20202,793202273521N/A
3/31/20202,837234261522N/A
12/31/20192,860242N/A514N/A
9/30/20192,873234N/A484N/A
6/30/20192,838217N/A380N/A
3/31/20192,806198N/A340N/A
12/31/20182,765195N/A314N/A
9/30/20182,706204N/A269N/A
6/30/20182,664218N/A330N/A
3/31/20182,571228N/A338N/A
12/31/20172,469220N/A325N/A
9/30/20172,382220N/A388N/A
6/30/20172,348220N/A390N/A
3/31/20172,350214N/A352N/A
12/31/20162,331206N/A325N/A
9/30/20162,339199N/A296N/A
6/30/20162,335200N/A269N/A
3/31/20162,310198N/A297N/A
12/31/20152,317199N/A324N/A
9/30/20152,370198N/A346N/A
6/30/20152,435193N/A346N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: ATR s prognostiserade vinsttillväxt ( 7.8% per år) är över sparkvoten ( 3.5% ).

Resultat vs marknad: ATR s intäkter ( 7.8% per år) förväntas växa långsammare än marknaden för US ( 16.4% per år).

Höga tillväxtresultat: ATR s intäkter förväntas växa, men inte avsevärt.

Intäkt vs marknad: ATR s intäkter ( 5.7% per år) förväntas växa långsammare än marknaden för US ( 11.4% per år).

Hög tillväxtintäkter: ATR s intäkter ( 5.7% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: ATR s avkastning på eget kapital förväntas bli låg om 3 år ( 12.6 %).

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/06 07:39
Aktiekurs vid dagens slut2026/05/06 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

AptarGroup, Inc. bevakas av 16 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Ghansham PanjabiBaird
Mark WildeBMO Capital Markets Equity Research
George StaphosBofA Global Research